Combination HIV prevention among MSM in South Africa: results from agent-based modeling by Brookmeyer, Ron et al.
Combination HIV Prevention among MSM in South
Africa: Results from Agent-based Modeling
Ron Brookmeyer1*, David Boren1, Stefan D. Baral2, Linda- Gail Bekker3, Nancy Phaswana-Mafuya4,
Chris Beyrer2, Patrick S. Sullivan5
1 Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America, 2 Center for Public
Health and Human Rights, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 3 Desmond Tutu HIV Centre, University of
Cape Town, Cape Town, South Africa, 4 HIV/AIDS, STI/TB Research Programme, Human Sciences Research Council, Port Elizabeth, South Africa, Office of the Deputy Vice
Chancellor, Research and Engagement, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa, 5 Department of Epidemiology, Rollins School of Public
Health, Emory University, Atlanta, Georgia, United States of America
Abstract
HIV prevention trials have demonstrated the effectiveness of a number of behavioral and biomedical interventions. HIV
prevention packages are combinations of interventions and offer potential to significantly increase the effectiveness of any
single intervention. Estimates of the effectiveness of prevention packages are important for guiding the development of
prevention strategies and for characterizing effect sizes before embarking on large scale trials. Unfortunately, most research
to date has focused on testing single interventions rather than HIV prevention packages. Here we report the results from
agent-based modeling of the effectiveness of HIV prevention packages for men who have sex with men (MSM) in South
Africa. We consider packages consisting of four components: antiretroviral therapy for HIV infected persons with CD4 count
,350; PrEP for high risk uninfected persons; behavioral interventions to reduce rates of unprotected anal intercourse (UAI);
and campaigns to increase HIV testing. We considered 163 HIV prevention packages corresponding to different intensity
levels of the four components. We performed 2252 simulation runs of our agent-based model to evaluate those packages.
We found that a four component package consisting of a 15% reduction in the rate of UAI, 50% PrEP coverage of high risk
uninfected persons, 50% reduction in persons who never test for HIV, and 50% ART coverage over and above persons
already receiving ART at baseline, could prevent 33.9% of infections over 5 years (95% confidence interval, 31.5, 36.3). The
package components with the largest incremental prevention effects were UAI reduction and PrEP coverage. The impact of
increased HIV testing was magnified in the presence of PrEP. We find that HIV prevention packages that include both
behavioral and biomedical components can in combination prevent significant numbers of infections with levels of
coverage, acceptance and adherence that are potentially achievable among MSM in South Africa.
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The identification of a single HIV intervention that is capable of
preventing large numbers of infections, such as a highly effective
vaccine, remains elusive. Nevertheless, in recent years there have
been enormous successes in identifying moderately effective HIV
prevention interventions. These interventions include both
behavioral and biomedical strategies. The question is how to
combine these moderately effective interventions into highly
effective prevention packages [1–3]. The idea is that multiple
interventions when used in combination could prevent more
infections than any single intervention used in isolation. Further-
more, the effectiveness of interventions when used in combination
may be synergistic.
Although the efficacies of various interventions applied in
isolation have been evaluated in a number of rigorous randomized
controlled trials, there is little direct evidence about the efficacy or
effectiveness of combinations of these interventions [4–7].
Estimates of the effectiveness of combinations of interventions
are important for guiding the development of prevention
strategies. Characterizing the effect sizes of combination preven-
tion interventions are critically important before embarking on
large scale randomized controlled trial to rigorously evaluate such
combination interventions to insure that the trials are adequately
powered [8–10].
The drivers of the global HIV MSM epidemics have been
previously reviewed highlighting the sustained HIV prevalence
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and often increasing HIV incidence among these men in several
epidemic contexts [11,12]. The majority of randomized trials in
the context of generalized HIV epidemics have focused on
heterosexual or vertical transmission of HIV with limited data
evaluating efficacy of interventions focused specifically on men
who have sex with men (MSM) [13].
Here we report the results from agent-based modeling of the
effectiveness of combination prevention interventions for MSM in
South Africa. The work is part of the Sibanye Health Project to
develop and test HIV prevention interventions among MSM in
South Africa. Agent-based modeling has been used to evaluate the
drivers of the HIV epidemic in several MSM populations [14].
Here our focus is the use of agent-based models to estimate the
overall effectiveness of combination prevention in terms of
percentages of infections prevented among MSM in South Africa.
Recently, there has been important modeling work of HIV
prevention strategies in MSM populations focusing on specific
interventions in various regions of the world such as HIV testing in
New South Wales [15], circumcision in Peru [16], and antiretro-
viral treatments including testing and linkage to care (but not pre-
exposure prophylaxis) in China [17]. While previous modeling
work on combination HIV prevention has been performed in
South Africa [18], those models have not focused on the MSM
population. This paper is focused on the evaluation of combina-
tion HIV prevention in the MSM population in South Africa. We
examine four components of combination prevention: treatment
of HIV infected persons with ART; prophylactic treatment of high
risk HIV uninfected persons to reduce risk of acquisition of HIV
infection (PrEP); counseling and condom promotion to reduce the
frequency of unprotected anal intercourse; and HIV antibody
testing. We perform a detailed statistical analysis of the simulation
results of the agent-based model to assess the stochastic variability
in the results and to borrow strength across all the simulations to
improve estimates of the effects of combination prevention.
Methods
Overview of Agent-based Model
Agent-based models are stochastic simulations of interacting
agents (e.g. individuals) who may alter behaviors in response to
other agents or changes in the environment [19–20]. We
developed an agent-based model to evaluate combination HIV
prevention interventions among MSM in South Africa. Here, we
describe the main features of the model which are also
summarized in Table 1. Further details and specific model
parameter values are given in the Supporting Information S1.
Each person (agent) is assigned values for variables associated
with risks for transmission and acquisition of HIV. The
distributions of these variables were chosen to match available
data from South Africa [21]. To simulate the heterogeneities in
risk across MSM populations, the values of the variables (e.g., level
of sexual activity, numbers of partners) were drawn from
probability distributions. The variables include level of and
predominant type of sexual activity (e.g., receptive or insertive
unprotected anal intercourse [22], numbers of regular partners,
whether or not the person is in a main partnership, frequency of
HIV antibody test screening, HIV infection status at baseline, and
for HIV infected persons, their CD4 levels and whether or not
receiving they were receiving ART at baseline. Persons were
assigned into variable sized networks of regular sexual partners.
One of those regular partners could also be assigned to be the
person’s main sexual partner. Persons were also allowed to have
sexual contact with persons outside their network of regular
partners (i.e., casual partners). The probability of sexual contact on
any day between two persons depended on whether the
partnership was between main partners (most likely), regular
partners (somewhat less likely) or casual partners (least likely).
The agent-based simulation proceeded day by day, starting at
baseline (which is defined as calendar time t = 0). On each day, we
simulated whether an HIV uninfected person had sexual contact
with an infected person for every possible pair of persons. If an
HIV uninfected person had contact with an infected person, we
simulated transmission occurrence. The probability of transmis-
sion was determined by factors that included the type of sexual
contact (e.g., insertive or receptive role in unprotected anal
intercourse (UAI)), antiretroviral treatment for the infected
partner, and oral Truvada-based pre-exposure prophylaxis (PrEP)
for the uninfected partner [5,23–25]. Persons also had an
opportunity to receive an HIV test. At the end of each day, the
infection status and CD4 cell count were updated [26]. Persons
were removed from the simulation when death occurred.
We considered four possible components of combination
prevention interventions and different intensity levels of these
components. One component was treatment of HIV infected
persons with ART [4]. Consistent with current South African
national standards, HIV infected persons with a CD4 ,350 who
had an HIV test within the preceding 6 months were eligible to
receive ART. We considered a range of values for the percentage
(X1) of persons eligible for ART and not already in treatment at
baseline who receive ART. Here X1 is measuring additional ART
coverage among eligible persons over and above those already
receiving ART at baseline. Data from South Africa indicated
approximately 50% of eligible persons are on ART and that value
was taken to be the baseline level of ART coverage [21].
A second component of combination prevention was prophy-
lactic treatment of high risk HIV uninfected persons to reduce risk
of acquisition of HIV infection with tenofovir/emtricitabine
(Truvada) (PrEP) [5]. HIV uninfected persons who had an HIV
test within the preceding 6 months and were at high risk (defined
as either .12 UAI acts in the preceding 6 months or having a
main partner who is HIV infected) were eligible to receive PrEP.
We considered various values for the percentage (X2) of eligible
persons who were offered and accepted PREP. Persons who
received PrEP were classified as either low or high adherers (see
online supplement for details). The model allowed adherence level
to modify the effectiveness of PREP in reducing risk of HIV
acquisition [28].
The third component was counseling and condom promotion to
reduce the frequency of UAI [29]. We considered a range of
values for the proportionate reduction in UAI contacts (X3). For
example, X3 = 15% refers to an intervention that successfully
reduces the rate of UAI by 15%. The fourth component was a
program to increase HIV antibody testing. We considered an
intervention component that decreased by one half the proportion
of persons who never receive an HIV antibody test, from 1/3 to 1/
6. The presence of this component in combination HIV
prevention intervention is indicated by X4 = 1 (otherwise X4 is
set to 0).
We considered combination prevention interventions consisting
of one or more of these four components: ART treatment
coverage; PrEP coverage, UAI reduction, and HIV testing
increase. We considered a range of for the levels of each
component (values for X1, X2, and X3, ranged between 0.0%
and 95%, and X4 took values 0 or 1. For example, a combination
HIV prevention intervention with X1 = 75%, X2 = 25%, X3 = 5%,
and X4 = 1 corresponds to a combination prevention intervention
with four components: ART given to 75% of all eligible persons
who were not already receiving ART at baseline; PrEP given to
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25% of eligible persons; a 5% reduction in the rate of occurrence
of UAI; and a halving of the proportion of persons who never
received an HIV test. We considered various combination
prevention interventions by varying the values of X1, X2, X3 and
X4, and performed multiple replications for each of those
combination prevention interventions. We performed replications
of the simulations to assess stochastic variation [27].
The number of replications was chosen to control the standard
error. Specifically, we calculated the standard error of the mean
proportion infected over 5 years after each replication using all
replications performed up to that point. If the standard error was
above 0.01 we proceeded and performed an additional replication.
We stopped replications when the standard error fell below.01.
The mean number of replications performed for a combination
intervention was 13 with a minimum of at least 5 replications
performed for each combination intervention. In addition, we
performed 60 replications for the control setting of no intervention
(i.e., each Xi = 0). We considered all packages corresponding to 4
levels each of ART coverage, 4 levels of PREP coverage, 4 levels of
UAI reduction and 2 HIV testing levels. In addition we considered
a number of additional packages of interest including when one or
more of the levels were 0 as well as some additional packages when
the UAI reduction was fixed at X3 = 15% which was a value
thought to be potentially achievable. In total we studied 163 HIV
prevention packages and a total of 2252 simulations run of the
agent-based model across all packages. Each simulation run was
carried out for a five year period. The agent-based models were
implemented in the statistical programming language R with the
multithreading package ‘snowfall’ to address the highly intensive
computational demands [30–31].
Statistical Analysis
We performed statistical analyses of the dataset of results from
the 2252 simulation runs of the agent-based model. The
dependent variable (y) was the cumulative proportion of MSM
that became HIV infected over 5 years from each run of the
simulation. We developed a statistical model to relate y (the
dependent variable) to the levels of the components (X1, X2, X3
and X4) in the combination prevention intervention (the explan-
atory variables). We used a generalized linear model with a logistic
link of the form, log(y/(1-y)) which we arrived at after model fitting
and regression diagnostics [32]. We considered both linear and
higher order polynomial terms (e.g. quadratic and cubic terms) for
the levels of the components (the X’s). We also considered
interaction terms between the components.
Because we performed replications of each combination
interventions we were able to evaluate the variance of y and
found that the variance of y was not constant across interventions
but varied with the magnitude of y. We found that a cubic
polynomial adequately described the relationship between the
variance of y and the expected value of y. Accordingly, we used
Table 1. Main characteristics of agent-based model for combination HIV prevention among MSM in peri-urban South Africa
(additional information and specific parameter values are in the Supporting Information S1).
Attributes assigned to each person at start
Frequency of sexual activity
HIV status at start
CD4 count at start if HIV +
Knowledge of HIV status at start (yes, no)
Sexual role preference (insertive, receptive, versatile)
HIV testing frequency (3 levels: moderate, low, never)
Some assigned a main partner
Proportion of sexual contacts that are UAI (2 levels)
Sexual networks of regular partners (allowance for sero-sorting)
Daily updates
Daily sexual contacts depends on type of partnership
Likelihood of contact (in decreasing order): main, regular, casual, have other main partners
HIV testing possible
UAI rate adjusted if learns knowledge of HIV status
CD4 levels updated for HIV positive
Infection status updated
Prevention Interventions
ART for eligible HIV positives
Eligible: HIV test within 6 months and CD4 ,350
Considered varying levels of coverage (X1)
PREP for eligible HIV negatives
Eligible: in last 6 months had both HIV test and .12 UAIs or had infected main partner
Varying levels of PREP acceptance (X2) with two levels of adherence (low and high)
Reduction in UAI frequency (considered varying reduction levels (X3))
Increase in HIV testing: convert 50% of the never testers to low frequency testers
doi:10.1371/journal.pone.0112668.t001
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iteratively reweighted least squares to account for the non-constant
variance and to estimate the regression coefficients in the model
for y [33]. We used the resulting model for y to calculate the
percent of HIV infections prevented for a combination interven-
tion with component levels X1, X2, X3, and X4 compared to no
intervention (i.e., when all the X’s are equal to zero). We
calculated confidence intervals for the percent of HIV infections
prevented that accounted for the covariance between regression
coefficients (see Supporting Information S1 for detail). The model
allows us to predict the percent of HIV infections that could be
prevented among MSM for any levels of the components of
combination prevention intervention. The statistical analyses were
performed with the R programming language [30].
Results
Figure 1 is a graphical display of the 2,252 simulation runs of
the agent-based model prior to any statistical modeling of the
results. Each data point corresponds to one of the 163
combination prevention interventions including the control setting
of no intervention. Each data point plots the average of the
cumulative percent of MSM who become HIV infected over five
years (y) versus the standard deviation of y based on all replications
performed for that intervention. The mean cumulative percent
infected over 5 years ranged as high as 26.4% when there was no
intervention (X1 = X2 = X3 = X4 = 0). As shown in the figure,
interventions that reduced the rate of UAI by at least 25%
succeeded in reducing the cumulative incidence of infection to less
than 15%, and thereby preventing at least 100 x (26.4–15)/
26.4 = 43.2% of HIV infections. The figure also shows that the
standard deviation of y increased with y; there was a decreasing
trend in the coefficient of variation of y (i.e., standard deviation/y)
from approximately 0.20 to 0.16.
The regression model equation for y is given in the online
supplement. Figure 2 is based on that equation and shows the
percentage of HIV infections prevented for a range of combina-
tion interventions that include: UAI reduction of 0 or 15%; PrEP
coverage of 0 or 50%; HIV testing increase that reduced the
proportions of persons who never test by 50%; and a continuous
range for incremental ART coverage (X1) over and above persons
already receiving ART at baseline. The figure shows that an
intervention with only a 15% UAI reduction and no other
component was superior to all other interventions that did not
include a UAI reduction component. The figure illustrates a
positive association between the percentage of infections prevented
and increasing ART coverage (X1), but the positive slope is small
and that finding is explained because X1, as defined here, refers
only to the additional ART coverage of eligible persons (,350
CD4 and an HIV test within the previous 6 months) who were not
already receiving ART at baseline. We consider this point further
in the Discussion Section. Figure 3 is similar to Figure 2 except it
includes interventions with UAI reduction of 25% and PrEP
coverage of 25%. The figure shows that a combination prevention
intervention with a 25% UAI reduction, 25% PrEP coverage, and
HIV testing increase (X2 = 25%, X3 = 25%, X4 = 1) can prevent
more than 35% of infections over five years.
To understand how high-impact prevention packages could be
constructed, we assumed that a basic prevention package would
include ART coverage of 50% of eligible persons. Table 2 shows
the effects of sequentially adding components to ART coverage to
create HIV prevention packages. We find that the addition of a
component that reduces UAI by 15% (X3 = 15%) would prevent
Figure 1. Results from 2252 simulations of agent-based model of HIV spread among MSM in South Africa corresponding to 163
distinct combinations of HIV prevention interventions. Each point represents replicates for a particular combination of HIV prevention
interventions. Plotted are the mean percentages infected over 5 years for each intervention (averaged over replicates) versus the standard deviations
of those percentages. Combination prevention interventions which included a $25% reduction in UAIs are indicated in dark blue, all others are
indicated in light blue. The data point in red corresponds to the 60 simulation runs for the control setting of no intervention.
doi:10.1371/journal.pone.0112668.g001
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an additional 20.3% of infections over and above the base package
(Package 1 in Table 2). That reduction in HIV infections from the
addition of a condom promotion/UAI reduction component to
the base package is considerably greater than that achieved from
the addition of a PrEP component with 50% coverage (which
yields an additional 9.5% of infections prevented) or an increase in
Figure 2. HIV infections prevented over 5 years from combination prevention interventions with four components. ART coverage of
eligible persons who were not already receiving ART at baseline, PREP with 50% acceptance (dotted lines), 15% UAI reduction (blue lines; no UAI
change are in red) and increase in HIV testing (black triangles). See Table 1 for further details about the components of the prevention interventions.
doi:10.1371/journal.pone.0112668.g002
Figure 3. HIV infections prevented over 5 years from combination prevention interventions with four components. ART coverage of
eligible persons who were not already receiving ART at baseline, PREP with 25% acceptance (dotted lines), 25% UAI reduction (blue lines; no UAI
change are in red) and increase in HIV testing (black triangles). See Table 1 for further details about the components of the prevention interventions.
doi:10.1371/journal.pone.0112668.g003
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HIV testing of previously untested men (which yields an additional
2.9% of HIV infection prevented). If we start with a package that
includes both 50% ART coverage and 15% UAI reduction
components (Package 2 in Table 2), we find that HIV infections
could be reduced by 10.1% with the addition of a PrEP
component (with 50% coverage) or, alternatively, reduced by
3.1% with the addition of an HIV testing component to reach men
never tested for HIV. If we start with a package that includes three
components, ART coverage, UAI reduction and PrEP compo-
nents (Package 3 in Table 2), we find that the addition of the HIV
testing component would further reduce infections by 4.9%. We
find that the impact of an HIV testing component is greater in the
presence of a PrEP component than without a PrEP component
(compare 4.9% to 2.9% and 3.1%).
Table 3 provides information about a four component combi-
nation prevention intervention and the contributions of each of the
components. The four component package included 50% ART
coverage of eligible persons, 50% PrEP coverage of eligible
persons, 15% UAI reduction and a 50% reduction in those never
tested for HIV. We estimate that this four component package of
combination interventions could prevent 33.9% of infections over
5 years (95% confidence interval (31.5, 36.3)) compared to no
intervention. We evaluated the incremental impact of each
individual component to that four component prevention package
by calculating the percent difference in infections with the four
component package and comparing that to a three component
package that excluded that individual component. For example,
the addition of a UAI component to a package that included the
other three components (ART, PrEP, and HIV testing) prevented
an additional 21% of infections. The UAI component had the
largest incremental effect. The addition of the PrEP component to
a package consisting of the other three components (ART, UAI
reduction, HIV testing) prevented an additional 11.7% of
infections. The UAI component had the greatest incremental
effect (21%) followed by the PrEP component, while the
incremental effects of ART coverage (over baseline levels) and
HIV testing were considerably smaller.
Discussion
In recent years significant progress has been made in HIV
prevention science. Findings from HIV prevention trials have
demonstrated the effectiveness of behavioral and biomedical
interventions such as earlier initiation of ART, PrEP, condoms
and behavioral change. The effectiveness of these interventions
will depend on their availability in communities as well as levels of
uptake and adherence by persons at risk. Each of these
interventions is only partially effective in preventing HIV
infections, and as such, no single intervention is expected to be
sufficient to eliminate the spread of HIV. HIV prevention
packages offer the potential to significantly increase the effective-
ness of any single intervention. HIV prevention packages offer
multiple approaches for reducing risks and possibilities of synergies
between the interventions. Quantification of the effectiveness of
HIV prevention packages is important for developing combina-
tions of interventions and for designing prevention trials of
combination prevention. Unfortunately most research to date has
focused on testing only a single intervention rather than HIV
prevention packages. In this report we used agent-based models to
evaluate the effectiveness of HIV prevention packages among
MSM in South Africa.
We identified a four component HIV prevention package for
MSM in South Africa which could prevent approximately 34% of
infections over five years. We single out this intervention for
discussion because it is a potentially achievable combination
package that we found to be particularly effective. That four
component package consists of 50% ART coverage for eligible
persons who were not already receiving ART at baseline, 50%
PrEP coverage for high risk eligible persons, 15% UAI reduction
and a 50% reduction in those who never test for HIV. The
component with the largest incremental impact on infections was
the 15% UAI reduction which prevented an additional 21% of
infections when added to a package of the other three components.
PrEP coverage had the second largest incremental impact,
followed by HIV testing and additional ART coverage over
baseline levels. We find that even small reductions in UAIs can
have huge effects.
We believe the target goals for coverage of each intervention
component of the four component package outlined above are
achievable in the MSM population in South Africa with concerted
commitments and prioritization for HIV prevention for MSM.
While the target goals for each component of the prevention
package are modest, those goals are at present not being met.
Currently, there is essentially no uptake of PrEP among MSM in
South Africa; most anal intercourse acts are not protected by
condoms; and significant numbers of men in South Africa have
not been tested for HIV. In order to achieve the scale of
Table 2. Incremental contribution from adding components to three prevention packages.
% infections prevented from adding components
to prevention packages (95% CI)1
Package 1 Package 2 Package 3
ART ART & UAI ART & UAI & PREP
Additional component
UAI (15% reduction) 20.3 (19.4, 21.3) — —
PREP (50% of eligible) 9.5 (8.4, 10.6) 10.1 (9.0, 11.2) —
HIV testing increase 2.9 (0.5, 5.4) 3.1 (0.5, 5.7) 4.9 (1.8, 7.9)
Table presents percent infections prevented from adding a component with 95% confidence intervals (CI). All packages include ART coverage of 50% of eligible persons
(from among those not already receiving ART at baseline). Additional components include PREP (50% acceptance of PREP among eligible persons), UAI reduction (15%
reduction), and HIV testing increase (50% reduction of persons who have never received an HIV test).
1The percent infections prevented refers to the percentage decrease in the 5 year cumulative HIV incidence with the HIV package that includes the additional
component into the base package.
doi:10.1371/journal.pone.0112668.t002
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interventions required for public health impact, the coordinated
efforts of government, clinicians, and community are required.
We found that the impact of HIV testing in prevention packages
depended on which other components were in the package, and
specifically, the impact of the HIV testing was magnified when
PrEP was included in the package. Such synergies make sense
because HIV testing is a gateway to access to PrEP. In this report,
we examined the effect of reducing the numbers of persons who
never receive an HIV test by half. The effect of an HIV testing
component in a prevention package would be greater if the never
testers were reduced by more than half or the HIV testing
frequencies were increased among persons that do test.
We found a modest effect of ART coverage relative to the other
components of the package. This finding was initially surprising
because other modeling work has demonstrated that ART can
have a significant impact on HIV incidence. For example, Eaton
and colleagues [34] performed a systematic review of models to
address the question of the impact of ART in a treatment- naı̈ve
population. They found that HIV incidence would be consider-
ably lower after 8 years if large numbers remain on ART
compared to a counterfactual scenario in which there is no ART.
However, Eaton and colleagues emphasize that their result
assumed a treatment-naı̈ve population at baseline, that is, the
Eaton work assumed ‘‘ART was introduced into the population
beginning in 2012 with no treatment provision prior to this which
is in contrast to the rapid scale up of treatment that has actually
occurred prior to 2012 in South Africa’’ [34]. An important
difference of the Eaton work from our work is that we are
evaluating the impact of extending ART coverage in the context of
significant numbers (50% of eligible persons) already receiving
ART at baseline rather than in a treatment-naı̈ve population.
Because we had significant numbers of persons receiving ART at
baseline, the impact of additional coverage of newly eligible
persons is smaller than if the population was treatment- naı̈ve at
baseline. ART eligibility requires an HIV test in the preceding 6
months and a CD4 count less than 350. Furthermore, the numbers
of persons becoming eligible for ART over the 5 year period (who
were not already eligible at baseline) were staggered over the 5
years and were not becoming eligible all at once in a bolus. For
example, in our simulation of the control (no intervention)
scenario, the number of persons receiving ART at baseline
(t = 0) was 55 persons out of 255 infected persons at baseline. In a
simulation of the four component package (50% ART coverage
for eligible persons who were not already receiving ART at
baseline, 50% PrEP coverage for high risk eligible persons, 15%
UAI reduction and a 50% reduction in those who never test for
HIV), the additional numbers of persons who would go on ART at
some time post-baseline during the subsequent 5 years is only 71
persons in addition to the 55 persons already receiving ART at
baseline. Furthermore, more than half of these additional 71
persons going on ART would in fact not begin ART until after 2.5
years post baseline (t.2.5). These numerical results illustrate that
in our simulation work, the incremental ART coverage over
baseline is relatively modest. In our modeling setting, the benefit of
ART is limited by the number of persons with clinical indication
(,350 CD4) who were not receiving ART at baseline and who
had an HIV test. As pointed out by Eaton and colleagues
‘‘comparing results and conclusions across models is challenging
because models have addressed slightly different questions’’ [34].
The impact of ART is driven by the numbers of treatment at
baseline, the treatment threshold, the sufficiency of HIV testing to
identify those living with HIV, and of course the extent to which
treatment is efficacious in reducing infectiousness. If the guideline
for treatment were to shift to CD4 count below 500 or an even
higher threshold, the impact of ART would be greater.
The impact of a PrEP component in a prevention package
depends on the eligibility requirement. In our work, the PrEP
eligibility requirement was either being in a sero-discordant main
partnership or having a very high rate of UAIs (12 per 6 months).
If that threshold for eligibility is lowered to expand the numbers
who are eligible, then the impact of PrEP would be greater than
reported here.
We performed considerable numbers of replications of our
agent-based modeling to account for stochastic variation. The
confidence intervals we report account for the stochastic variation.
However, as in all agent-based models, our model is based on
numerous assumptions and input parameters. Many aspects of our
model such as the networks of sexual partners, distributions of
numbers of partners and baseline frequencies of UAIs relied on
limited data. Furthermore, the regular and main partners did not
change over the 5 years of the simulation. We did however allow
persons to have contacts outside their network of regular partners
(casual partners). We only forecast five years in an attempt to limit
the sensitivity of the results to these model simplifications. More
reliable information about partner formation and dissolution
among the MSM population on South Africa is important to
further inform models of HIV prevention. We focused on the
MSM population and did not attempt to model the dynamics of
Table 3. Contribution of four components of an HIV prevention package to infections prevented.
Prevention package component percent infections prevented due
to addition of component (95% CI)1
ART (50% coverage of eligible persons) 3.4 (2.2, 4.5)
PREP (50% coverage of eligible persons) 11.7 (8.4, 15.0)
UAI (15% reduction) 21.0 (20.0, 22.0)
HIV testing increase 4.9 (1.8, 7.9)
% prevented with all 4 components2 33.9 (31.5, 36.3)
Components include ART (50% ART coverage of eligible persons from among those not already receiving ART at baseline); PREP (50% acceptance of PREP among
eligible persons); UAI reduction (15% reduction), and HIV testing increase (50% reduction of persons who never have an HIV test).
1The percent infections prevented due to component i refers to the percentage decrease in the 5 year cumulative HIV incidence with the HIV package that includes all
four components compared to the HIV prevention package that includes three of the four components leaving out component i.
2The total percent infections prevented refers to the percentage decrease in the 5 year cumulative incidence with the 4 component HIV package compared to no
prevention interventions (none of the components). The total percent is not the column sum of the individual components.
doi:10.1371/journal.pone.0112668.t003
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transmission within and across other risk groups such as
intravenous drug users. We also did not model variable
infectiousness over time. We did not account for new incoming
MSM to the population although that simplification may have a
small effect over the five years the simulations were run. We
recognize that caution should be exercised when interpreting the
findings from agent-based models that rely on many simplifica-
tions and assumptions. As such, we focused on presenting the
results in terms of relative effects of a prevention package (e.g., the
percent of infections averted with a prevention package compared
to no intervention) because relative effects may be less sensitive to
model assumptions than the absolute cumulative number of
infections. Nevertheless, caution should still be exercised as with all
modeling results. In spite of these limitations, we believe agent-
based modeling offers a useful tool for approximating the
effectiveness of HIV prevention packages when direct empirical
data from comparative studies of combination HIV prevention is
unavailable.
Further research on understanding associations within individ-
uals with regard to uptake and adherence levels across the various
components of a prevention package will help to refine our
models. For example, identification of subgroups that are resistant
to accepting or adhering to any intervention would be important
for modeling and also for helping to design packages to overcome
barriers to acceptance of HIV prevention.
The HIV epidemic among MSM in South Africa continues to
grow. Obtaining sufficiently high levels of coverage, acceptance
and adherence with any single biomedical or behavioral interven-
tion is a major obstacle to controlling epidemic growth.
Combination HIV prevention offers the possibility of preventing
significant numbers of infections with sufficient levels of coverage,
acceptance and adherence; these levels are achievable with the
concerted efforts of multiple stakeholders. In the context of a
vigorous debate about the roles of behavioral and biomedical
interventions, our results are reconciling in that we demonstrate
that traditional HIV prevention activities, such as condom
promotion and HIV testing programs, still play vital roles in the
context of biomedical prevention. HIV prevention packages that
include both behavioral and biomedical components can, in
combination, prevent significant numbers of infections among
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